GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antengene Corp Ltd (FRA:722) » Definitions » Construction In Progress

Antengene (FRA:722) Construction In Progress : €0.00 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Antengene Construction In Progress?

Antengene's quarterly construction in progress increased from Jun. 2023 (€0.08 Mil) to Dec. 2023 (€21.02 Mil) but then declined from Dec. 2023 (€21.02 Mil) to Jun. 2024 (€0.00 Mil).

Antengene's annual construction in progress declined from Dec. 2021 (€13.01 Mil) to Dec. 2022 (€8.42 Mil) but then increased from Dec. 2022 (€8.42 Mil) to Dec. 2023 (€21.02 Mil).


Antengene Construction In Progress Historical Data

The historical data trend for Antengene's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antengene Construction In Progress Chart

Antengene Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Construction In Progress
Get a 7-Day Free Trial 6.37 13.01 8.42 21.02 -

Antengene Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.42 0.08 21.02 - -

Antengene Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


Antengene Business Description

Traded in Other Exchanges
Address
1065 West Zhongshan Road, Suites 1206-1209, Block B, Zhongshan SOHO Plaza, Changning District, Shanghai, CHN
Antengene Corp Ltd is a clinical-stage biopharmaceutical company focused on oncology medicines. The company produces drugs such as selinexor, eltanexor, verdinexor, and other products. It also engages in the discovery, development, manufacturing, and commercialization of first-in-class therapeutics for the treatment of hematologic malignancies and solid tumors. Geographically it operates in Chinese Mainland, Hong Kong, Macao and Taiwan and Overseas.

Antengene Headlines

No Headlines